Streetbeat News

Analyst Ratings

AMWL

Needham analyst Ryan MacDonald has reiterated a Hold rating on American Well (NYSE:AMWL).

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 11:05 am

SIRI

Morgan Stanley analyst Cameron Mansson-Perrone has reinstated an Underweight rating on Sirius XM Holdings with a $23 price target.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 11:02 am

GEV

Guggenheim analyst Joseph Osha has initiated coverage on GE Vernova with a Buy rating and set a price target of $300.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 11:00 am

BNTX

Morgan Stanley has upgraded BioNTech (NASDAQ:BNTX) from Equal-Weight to Overweight and increased the price target from $93 to $145, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 11:00 am

BDTX

HC Wainwright & Co. has reiterated its Buy rating for Black Diamond Therapeutic (NASDAQ:BDTX) and maintained a price target of $11.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 10:55 am

KOD

HC Wainwright & Co. has reiterated a Neutral rating for Kodiak Sciences (NASDAQ:KOD) and maintained a $3 price target.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 10:52 am

BHVN

HC Wainwright & Co. has reiterated its Buy rating on Biohaven (NYSE:BHVN) and maintained a price target of $59, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 10:50 am

REGN

Leerink Partners has downgraded Regeneron Pharmaceuticals from Outperform to Market Perform and reduced the price target from $1175 to $1077.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 10:49 am

CRGY

Evercore ISI Group has reinstated an Outperform rating on Crescent Energy (NYSE:CRGY) with a price target of $17, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 10:48 am

RNA

Goldman Sachs has initiated coverage on Avidity Biosciences with a Buy rating and set a price target of $59.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 10:45 am